PTC Therapeutics 2024年第四季度调整后每股收益$(0.85) 低于预期$(0.66),销售额$2.13亿 低于预期$2.3244亿

财报速递
28 Feb
PTC Therapeutics(纳斯达克代码:PTCT)报告季度每股亏损$(0.85),低于分析师一致预期的$(0.66),差距为28.79%。与去年同期每股亏损$(0.24)相比,同比下降254.17%。公司报告季度销售额为$2.13亿美元,低于分析师一致预期的$2.3244亿美元,差距为8.36%。与去年同期的$3.0706亿美元销售额相比,同比下降30.63%。

以上内容来自Benzinga Earnings专栏,原文如下:

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.66) by 28.79 percent. This is a 254.17 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $213.00 million which missed the analyst consensus estimate of $232.44 million by 8.36 percent. This is a 30.63 percent decrease over sales of $307.06 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10